INTRODUCTION
Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) is a recently identified inflammatory biomarker that may be involved in cardiovascular disease pathogenesis. Epidemiologic studies have consistently shown a positive association with coronary artery disease (CHD) for both Lp-PLA 2 concentration (1-5) and Lp-PLA 2 activity (5-9) in both healthy populations (3, 6, 7) and clinical populations (1, 2, 4, 5, 8, 9) .
Lp-PLA 2 is secreted by monocytes, macrophages, T lymphocytes, and mast cells and binds to the carboxy terminus of apolipoprotein B-100 to circulate with LDL cholesterol (10) . Eighty percent of Lp-PLA 2 circulates bound to LDL cholesterol, 10-15% circulates with HDL cholesterol, and the remaining 5-10% circulates with VLDL cholesterol or Lp(a) (11) . Lp-PLA 2 is believed to contribute to atherogenesis by promoting inflammatory processes in the arterial intima. Lp-PLA 2 enters the artery wall bound to LDL cholesterol, and once LDL cholesterol becomes oxidatively modified, Lp-PLA 2 hydrolyzes the sn2 ester bond of oxidized phospholipids, generating 2 proinflammatory compounds that act within the intima of atherosclerotic lesions to recruit chemokines and activate inflammation (12, 13) . Recent experimental evidence suggests that Lp-PLA 2 may be most etiologically relevant in the progression of atherosclerotic lesions to rupture-prone plaques (14, 15) .
Although Lp-PLA 2 may play a causal role in atherogenesis, little is known about modifiable lifestyle characteristics that may alter circulating Lp-PLA 2 activity levels. Many studies have found correlations between Lp-PLA 2 and triglycerides, LDL cholesterol, HDL cholesterol, body mass index (BMI), metabolic syndrome, age, sex, and smoking (2, 3, 7, (16) (17) (18) (19) (20) . In most studies the associations with triglycerides (21) , LDL cholesterol (16, 22) , and sex (16, 22, 23) persist after multivariable adjustment. However, previous studies have mostly only examined demographics and other biomarker variables, which, although interesting, are largely not directly modifiable. One recent trial examined the effect of supplementation with n23 polyunsaturated fatty acids and found no effect on Lp-PLA 2 (24) . However, no study has examined general dietary predictors of Lp-PLA 2 . The aim of this study was to examine a wide variety of dietary, biomarker, lifestyle, and clinical predictors of Lp-PLA 2 activity among adult men and women.
SUBJECTS AND METHODS

Study population
The Nurses' Health Study (NHS) is a prospective cohort study of 121,700 US female nurses who were 30-55 y of age at baseline in 1976. The Health Professionals Follow-Up Study (HPFS) is a prospective cohort study of 51,529 US male dentists, veterinarians, pharmacists, optometrists, osteopathic physicians, and podiatrists who were 40-75 y of age at baseline in 1986. Between 1989 and 1990, 32,826 women provided a blood sample and between 1993 and 1994, 18,159 men provided a blood sample. Through 30 June 2004, we documented an incident myocardial infarction (MI) in 443 men and 431 women from these blood cohorts, who were free of cardiovascular disease and cancer at the time blood was drawn (25, 26) . With the use of risk set sampling, 2 controls free of cardiovascular disease and cancer at blood draw and up to the date of diagnosis of the paired case were chosen randomly and matched for age (6 1 y), smoking (never, past, current: 1-14 cigarettes/d or !15 cigarettes/d), and month of blood draw. Among women, controls were also matched for fasting status and reported problems during the blood draw. The present study examined the 853 female and 878 male controls from this case-control study. We included controls whose matched case was confirmed as having CHD as well as those controls whose matched case was initially flagged as having CHD but through a medical record review was determined to not have CHD. This study was approved by the institutional review board of Brigham and Women's Hospital and the Human Subjects Committee Review Board of the Harvard School of Public Health.
Blood collection and laboratory measurements
Men and women were sent a blood collection kit that included instructions and supplies (blood tubes, tourniquet, gauze, bandages, and needles). Blood samples from men were collected into EDTA-containing blood tubes and from women into heparincontaining blood tubes. The samples were chilled and sent back by overnight courier. The samples were centrifuged on arrival at the laboratory and were subsequently placed in cryotubes as plasma, buffy coat, and red blood cells. Cryotubes were then stored in liquid nitrogen freezers at 2130°C or lower.
Lp-PLA 2 activity was measured by CAM-colorimetric activity test automated assay performed on a clinical chemistry analyzer with a colorimetric substrate for Lp-PLA 2 , which is similar to platelet activating factor with the addition of a nitrophenol label at the sn2 position. Hydrolysis of the colorimetric substrate was monitored by observing changes in visible absorbance over time (nmol Á min 21 Á mL 21 ) by using a standard curve for nitrophenol absorbance. CVs were 4.3% in women and 4.7% in men. In a subset of men who provided 2 blood samples 1 y apart (n = 15), the intraclass correlation coefficient for Lp-PLA 2 activity was 0.85.
Concentrations of total cholesterol, triglycerides, and HDL cholesterol were measured simultaneously with a Hitachi 911 analyzer by using reagents and calibrators from Roche Diagnostics (Indianapolis, IN); CVs were ,1.8% in both men and women. LDL-cholesterol concentrations were measured by using a homogenous direct method from Genzyme (Cambridge, MA); CVs were ,3.1% in both men and women. Glycated hemoglobin (Hb A 1c ) concentrations were based on turbidimetric immunoinhibition with hemolyzed whole blood or packed red cells; CVs were ,3.0% in both men and women. Intercellular adhesion molecule 1 (ICAM-1) was measured with a commercial enzyme-linked immunosorbent assay (R & D Systems, Minneapolis, MN); CVs were ,3.6%. In men, C-reactive protein (CRP) was measured by using immunoturbidimetry with reagents and calibrators from Denka Seiken (Niigata, Japan); CVs were ,2.8%. In women, CRP was measured with the US CRP ELISA kit (Diagnostic Systems Laboratories Inc, Webster, TX); CV was ,5.1%.
Assessment of lifestyle exposures
Both cohorts were followed through biennially mailed questionnaires to collect information on lifestyle factors and health behaviors. On the biennial questionnaires, the participants provided information about their age, weight, smoking status, aspirin use, cholesterol-lowering medication use, hormone therapy use (women only), and physical activity. We calculated BMI as the ratio of weight (in kg) over height squared (in m); self-reported weight was strongly correlated (r = 0.97) with independently measured weight in a validation substudy from this population of men and women (27) . Physical activity was calculated as metabolic equivalents (METs) per week by using the duration of moderate or vigorous forms of exercise multiplied by the intensity of the activity (28) . History of hypertension, history of high cholesterol, and family history of MI were determined from self-reports before blood collection.
We obtained dietary information with a 131-item selfadministered semiquantitative food-frequency questionnaire (sFFQ). Participants were asked to indicate how frequently, on average, they consumed particular food items over the course of the past year. Average macronutrient and micronutrient consumption were calculated by using nutrient values from the Harvard University Food Composition Database. Dietary intake collected by using the sFFQ has been shown to be a valid estimator of relative food intake when compared with multiple diet records (29, 30) . In addition, alcohol intake assessed by using the sFFQ was highly associated with alcohol intake assessed by using multiple diet records in women (r = 0.90) and men (r = 0.86) (31) . Dietary variables used in the present analyses included total calories, carbohydrates, protein, total fat, saturated fat, polyunsaturated fat, monounsaturated fat, trans fat, and alcohol.
Statistical analysis
Age-adjusted Spearman correlations were used to determine correlations between cardiovascular disease risk factors and Lp-PLA 2 activity. Multivariable linear regression models were used to predict mean Lp-PLA 2 activity by using dietary, biomarker, and lifestyle and clinical variables. We used robust variance estimates to allow for valid statistical inference without the need for normal distribution assumptions (32) . Clinical and lifestyle variables included age (5-y age categories), BMI (in kg/m 2 : ,25, 25-29.9, and !30), smoking (never, past, and current), physical activity (per 20 METs/wk), aspirin use (yes or no), cholesterol-lowering medication use (yes or no), hormone replacement therapy (never, past, and current; women only), history of hypertension (yes or no), history of diabetes (yes or no), DIETARY AND LIFESTYLE PREDICTORS OF LP-PLA 2 and family history of MI (yes or no). To model dietary variables, we used multivariable energy density models to estimate the change in mean Lp-PLA 2 activity associated with a 5% energy substitution of carbohydrate for protein, saturated fat, monounsaturated fat, or polyunsaturated fat and a 1% substitution of carbohydrate for trans fat. Alcohol was modeled per 15 g/d of consumption. All models were adjusted for total energy intake. LDL cholesterol is the primary carrier of Lp-PLA 2 and has been shown to be strongly related to Lp-PLA 2 activity, as has HDL cholesterol. Previous studies have suggested that CRP and Lp-PLA 2 act in separate inflammatory pathways and are uncorrelated, but no study has examined the relation between these 2 inflammatory biomarkers after multivariable adjustment.
Therefore, we chose to analyze and adjust for these biomarkers. We did not conduct these analyses with triglycerides or ICAM because of insufficient numbers of participants with these measurements and did not include apolipoprotein B because of its close relation with LDL cholesterol. LDL cholesterol and HDL cholesterol were modeled per 1-SD increase in the biomarker, and CRP was modeled as the log of the biomarker. If there was an absence of heterogeneity of results between the NHS and HPFS as determined by the Q statistic (33), we pooled the results from the men and the women by weighting each estimate by the inverse of its variance using STATA statistical software (StataCorp, College Station, TX). All other analyses were performed by using SAS software (version 9.1; SAS Institute Inc, Cary, NC) and were conducted separately for men and women.
RESULTS
Mean levels of Lp-PLA 2 activity were higher among men than among women ( Table 1 and Table 2 ). Lp-PLA 2 had modest and significant positive associations with age, total cholesterol, LDL cholesterol, apolipoprotein B, and BMI and inverse associations with HDL cholesterol in both men and women ( Table 3) .
To assess the independent relations of dietary, clinical, lifestyle, and biomarker variables with Lp-PLA 2 activity, we used multivariable linear regression models to predict mean Lp-PLA 2 activity. Except where noted, there were no significant differences in the estimated effect on Lp-PLA 2 activity between men and women for included characteristics; thus, sex-specific and pooled estimates are presented ( Table 4) . After mutual multivariable adjustment whereby all variables were included in the same model, providing estimates adjusted for all other model variables, many clinical and lifestyle variables were significantly related to Lp-PLA 2 activity (Table 4 A history of high cholesterol was associated with higher Lp-PLA 2 activity (b = 15.07; 95% CI: 11.31, 18.83). We examined the role of cholesterol-lowering medication use on Lp-PLA 2 activity levels separately for participants with and without a history of high cholesterol. For those with a history of high cholesterol, cholesterol-lowering medication use was associated with lower levels of Lp-PLA 2 activity (b = 29.60; 95% CI: 218.15, 21.05). For those without a history of high cholesterol, participants taking cholesterol-lowering medication had higher levels of Lp-PLA 2 activity, although there were few participants in this treated category, and the relation was not statistically significant (b = 5.00; 95% CI: 23.40, 13.41). In addition, all b coefficients were unchanged when we excluded the 22 women and 61 men who used cholesterol-lowering medication at the time of blood draw (data not shown).
Nutritional variables were also associated with Lp-PLA 2 activity. To assess the relation between nutrients and Lp-PLA 2 activity, we used nutrient density models that estimate the effect of substituting various macronutrients for carbohydrates. It is an isocaloric model and thus represents a change in diet rather than a mere addition of any given macronutrient. With this model, every 5% of energy consumed as protein instead of carbohydrate was associated with a 2.17 nmol Á min 21 Á mL 21 (95% CI: 0.43, 3.09) lower level of Lp-PLA 2 activity. Also, a 15-g increase in alcohol intake was associated with lower Lp-PLA 2 activity levels. (b = 24.36; 95% CI: 26.35, 22.37). The magnitude of the associations from a parsimonious model that only adjusted for statistically significant potentially modifiable predictors (postmenopausal hormone use, current smoking, cholesterol medication use among those with high cholesterol, overweight, aspirin use, alcohol intake, and protein intake) and additional conceptually necessary risk factors (age, obesity, past smoking, and total calories consumed) is shown in Figure 1 . Restricting the multivariable model to just these factors did not materially alter any estimates.
We also assessed the associations above after adjusting for LDL cholesterol, HDL cholesterol, and CRP. LDL cholesterol, 21.28) , and the relation between monounsaturated fat and Lp-PLA 2 activity was strengthened (b = 5.05; 95% CI: 0.17, 9.92). A 5% energy increment in consumption of monounsaturated fat (as a replacement of energy from carbohydrates) was associated with a 5.05 nmol Á min 21 Á mL 21 higher level of Lp-PLA 2 activity. Including these biomarkers in the model increased the R 2 from 0.14 to 0.41 in women and from 0.09 to 0.34 in men.
Use of postmenopausal hormones is associated with an alteration in lipid profiles. We therefore tested for effect modification of these relations by postmenopausal hormone status. In all multivariable models, the relations between dietary, lifestyle, clinical, and biomarker factors and Lp-PLA 2 activity were essentially unchanged (data not shown).
DISCUSSION
In this cross-sectional study of apparently healthy men and women, potentially modifiable clinical variables, including body 1 MET-h, metabolic equivalent hours. 2 Estimate derived from multivariable linear regression models with all variables in the model mutually adjusted for all other variables listed and also adjusted for total calories consumed.
3 Estimate derived from pooled results from the men and women by weighting each estimate by the inverse of its variance. 4 P , 0.01. 5 P , 0.05. 6 P , 0.001. 7 Q statistic P , 0.05; thus, it is not valid to combine estimates from the NHS and HPFS. 8 Postmenopausal hormone use not applicable in men. 9 Among those with a history of high cholesterol.
weight, smoking, and use of cholesterol-lowering medication, postmenopausal hormones, and aspirin were independently associated with higher levels of Lp-PLA 2 activity. In addition, alcohol and protein intakes were inversely associated with Lp-PLA 2 activity, which suggests that nutritional factors may have the potential to influence Lp-PLA 2 activity. This is the first study to examine associations between dietary factors and Lp-PLA 2 activity in a large cross-sectional study of men and women. Alcohol intake was inversely associated with Lp-PLA 2 activity. It is well documented that moderate alcohol intake lowers the risk of CHD, an effect that is likely primarily mediated through alcohol's ability to increase HDL-cholesterol concentrations (34, 35) . In our analysis, adjustment for HDL cholesterol, but not for LDL cholesterol, attenuated the association with Lp-PLA 2 activity (data not shown). Thus, the alcoholmediated alterations in HDL cholesterol may explain the relation between alcohol intake and Lp-PLA 2 activity. Consumption of protein relative to carbohydrate intake was associated with decreased Lp-PLA 2 activity. Controlled feeding studies suggest that replacing carbohydrates with protein can favorably alter plasma lipid profiles by both increasing HDL cholesterol and decreasing LDL cholesterol and triglycerides (36) . However, per our results, the relation between protein and Lp-PLA 2 activity was essentially unchanged after adjustment for LDL cholesterol and HDL cholesterol, which suggests that an effect of protein on Lp-PLA 2 activity may be due to mechanisms other than protein's affect on lipid concentrations. In a recent small interventional study that assessed the effect of a low-calorie diet on Lp-PLA 2 activity levels, Tzotzas et al (37) found that an average 10-kg weight loss achieved over 4 mo was associated with a 10% decrease in Lp-PLA 2 activity. All participants received the same low-calorie diet and, thus, the effect of specific nutrients on Lp-PLA 2 activity could not be distinguished from the effect of weight loss on Lp-PLA 2 activity. However, this evidence in conjunction with the modest associations observed in our study suggest that diet may represent a potentially modifiable pathway through which Lp-PLA 2 activity can be altered.
Lp-PLA 2 activity levels were higher among men than among women, a finding that has been consistently observed across other studies (2, 7, 16, 19, (38) (39) (40) (41) . This could be due to an estrogen-mediated down-regulation of Lp-PLA 2 activity (42). This sex difference could also be due to lower concentrations of LDL cholesterol among women. LDL cholesterol is both the primary carrier of Lp-PLA 2 and, in its oxidized form, is the primary substrate on which Lp-PLA 2 activity operates. Lower concentrations of LDL cholesterol could result in both a decreased circulation of Lp-PLA 2 and decreased substrate for this enzyme. However, after adjustment for LDL-cholesterol and HDL-cholesterol concentrations, postmenopausal hormone use was still inversely associated with Lp-PLA 2 activity. Thus, this does support a direct independent down-regulatory effect of estrogen on Lp-PLA 2 activity.
Eighty percent of Lp-PLA 2 circulates bound to LDL cholesterol, and up to an additional 15% circulates with HDL cholesterol (43, 44) . Many of the modifiable cardiovascular disease risk factors we examined in this study can affect LDL-cholesterol and HDL-cholesterol concentrations. Thus, we chose to primarily analyze our data without initially adjusting for these lipid variables because they may be on the causal pathway . However, when we did adjust for LDL cholesterol and HDL cholesterol, we observed a modest attenuation of certain variables, particularly a history of high cholesterol, cholesterol-lowering medication use, postmenopausal hormone use, and current smoking. Lipid variables do appear to be the most important determinant of Lp-PLA 2 activity, as evidenced by the fact that a model that did not include LDL cholesterol and HDL cholesterol only explained 9% of the variation in Lp-PLA 2 in men and 14% in women, whereas 34% of the variation in men and 41% in women was explained after LDL cholesterol and HDL cholesterol were included.
After multiple adjustment for traditional risk factors, we observed an inverse association between CRP and Lp-PLA 2 activity, which was consistent with the findings for Lp-PLA 2 mass among women in the Hormones and Biomarkers Predicting Stroke Study of the Women's Health Initiative (45) and for Lp-PLA 2 activity among men in the Dallas Heart Study (46) . Most studies have found weak or no associations between CRP and Lp-PLA 2 (1, 7, 18, 19, 38, 39, (47) (48) (49) , which potentially reflects disparate inflammatory pathways toward CHD (47) . However, these studies did not provide multivariable adjustment for other biomarkers or clinical risk factors, and the present study provides evidence of a relation between these 2 inflammatory biomarkers.
We found a significant association between smoking and Lp-PLA 2 activity, a finding seen across some (16, 40, 41, 50) but not all (2-4, 7, 19) studies. However, most other studies assessed this association with little or no adjustment for other lifestyle characteristics, and there were differences across studies in how smoking was characterized. Smoking was associated with increased LDL cholesterol (51) and has been shown to increase oxidative modification of LDL (52, 53) . Thus, smoking may increase both the carrier and the substrate for Lp-PLA 2 .
In the present study, being overweight was also associated with Lp-PLA 2 , a finding that has been observed previously (16) . However, the relation with body weight was not linear and was not significantly associated in obese individuals. This may have been due to model instability at the high end of BMI, although a study among elderly US men and women reported a similar nonlinear relation (54) . In our analyses, the association between BMI and Lp-PLA 2 was fully attenuated after adjustment for several lipid biomarkers. A study in a Japanese population found that, after adjustment for LDL cholesterol and HDL cholesterol, BMI was inversely associated with Lp-PLA 2 (22) . It is possible that the relation between BMI and Lp-PLA 2 is mediated entirely through the lipid pathways, but this relation is likely more complex and warrants further study.
Results from a recent meta-analysis of 6 major trials of aspirin use to prevent cardiovascular disease suggest a decreased risk of CHD among aspirin users (55) . A recent study of Lp-PLA 2 mass and stroke found that Lp-PLA 2 was inversely associated with aspirin use among controls, although this association was not adjusted for other risk factors (45) . Because aspirin has antiinflammatory properties, it is paradoxical that the use of aspirin was positively associated with Lp-PLA 2 activity in the present study. It is possible that participants with a perceived high level of baseline risk began an aspirin regimen for cardioprotection, leading to channeling bias or confounding by indication. However, the relation between aspirin use and Lp-PLA 2 activity persisted after adjustment for traditional clinical risk factors, including high cholesterol, hypertension, diabetes, smoking, and family history of heart disease. This relation also persisted after adjustment for biomarkers. Interestingly, in the present study, aspirin use had a similar positive association with LDLcholesterol concentrations in a multivariable-adjusted model (data not shown). Thus, further studies are needed to determine the nature of these relations.
This study had several limitations. First, the analysis was based on cross-sectional data and, thus, causality cannot be inferred. However, clinical, dietary, and lifestyle factors were measured 2-4 y before participants provided blood samples. Thus, although there is still potential for confounding by indication as described above, reverse causality was unlikely. Second, both the questionnaire and biomarker data were susceptible to some degree of measurement error. However, the FFQ questionnaire used has been shown to assess diet with adequate validity when compared with multiple diet records (29, 30) , and errors due to self-report methods are unlikely to be related to Lp-PLA 2 activity. Thus, any misclassification would be nondifferential and, if anything, biased these results toward the null. It should also be noted that we measured circulating Lp-PLA 2 activity and could not measure Lp-PLA 2 activity in the plaque or intima itself, where it may be of most biological relevance.
In conclusion, we found that not smoking, use of postmenopausal hormones, having a BMI 25, increased alcohol consumption, and increased protein consumption all represent modifiable factors that favorably influence Lp-PLA 2 activity. Clinical interventions that aim to favorably influence the lipid profile may confer a beneficial effect on Lp-PLA 2 . However, this study suggests that the identified modifiable variables may affect Lp-PLA 2 activity independent of their effects on the lipid profile. Because Lp-PLA 2 activity may represent a novel pathway associated with increased CHD, it is necessary to identify other modifiable factors that influence Lp-PLA 2 activity.
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